Search

Displaying results 5311 - 5320 of 10000 in total
  1. Drug

    PBI-1402

    go.drugbank.com/drugs/DB05480
    Experimental

    PBI-1402 appears to work on the PMN pathway, but its specific binding properties are not known. PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator. … However, it has been shown that when co-administered with these compounds, effects are additive, making PBI-1402 an excellent candidate for combination therapy and asserting its independent mechanism of

  2. Drug

    Potassium carbonate

    go.drugbank.com/drugs/DB13977
    Approved

    Potassium carbonate (K2CO3) is a white salt, soluble in water (insoluble in ethanol) which forms a strongly alkaline solution.

    Mixtures: ZOLFO E POTASSIO CARBONATO NEW.FA.DEM., ZOLFO E POTASSIO CARBONATO NEW.FA.DEM.
  3. Drug

    Tivantinib

    go.drugbank.com/drugs/DB12200
    Investigational

    Tivantinib has been investigated in Solid Tumors.

  4. Drug

    GTX-758

    go.drugbank.com/drugs/DB14969
    Investigational

    GTX-758 is under investigation in clinical trial NCT01420861 (GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer).

  5. Drug

    Palifosfamide

    go.drugbank.com/drugs/DB05668
    Investigational

    Ifosfamide has been shown to be effective in high doses in treating testicular cancer, sarcoma and lymphoma.

  6. Drug

    Phencyclidine

    go.drugbank.com/drugs/DB03575
    ExperimentalIllicit

    Phencyclidine is similar to ketamine in structure and in many of its effects. Like ketamine, it can produce a dissociative state. … It exerts its pharmacological action through inhibition of NMDA receptors (receptors, N-methyl-D-aspartate). As a drug of abuse, it is known as PCP and Angel Dust.

  7. Drug

    Sirna-027

    go.drugbank.com/drugs/DB05896
    Investigational

    Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. S...

  8. Drug

    LX6171

    go.drugbank.com/drugs/DB05180
    Investigational

    LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia

  9. Drug

    Drinabant

    go.drugbank.com/drugs/DB05750
    Investigational

    It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease. … AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.

  10. Drug

    Halothane

    go.drugbank.com/drugs/DB01159
    ApprovedVet approvedWithdrawn

    A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce suffi...